NangioTx’s flagship product is an injectable drug, V-10, that helps create new blood vessels to treat root canals. NangioTx' injectable hydrogel creates a tissue regenerative matrix. Additionally, V10 has shown animal efficacy in treating peripheral artery disease ($14B market) and a funded Phase I SBIR for efficacy in diabetic wound healing. Business model is to sell doses for $100 each at 90% profit margin (1 dose/root canal)
Every year over 15M in the US and 75M Worldwide have root canals filled with rubber rods (gutta percha) resulting in dead teeth. Prone to infection, bone resorption and brittleness; these tombstones often require ~6-8 revisions/ tooth. The Holy Grail of Regenerative Endodontic Therapy (RET) is to develop a material that promotes in vivo regeneration of pulp-like tissue with regenerated blood vessels (vPLT).
Graduates of Bioventures and Masschallenge, Won OPEN houston pitch competition in 2015
NHLBI SMARTT grantee (2015) Phase I SBIR ($225K non-dilutive, 2019). 2 Pending Patents with exclusive rights out of Rice U. Proven efficacy in animal models.
